NAX Strengthens Leadership Team With Appointment of Patrick Nicolet - Former Capgemini Group CTO
9.9.2021 15:00:00 EEST | Business Wire | Press release
New Asset eXchange (NAX), a company that creates new markets and ecosystems around corporate assets, has today announced the appointment of Patrick Nicolet as Chair of its technology platform, Bridge.
Patrick Nicolet - formerly Group CTO and Executive Board Member at Capgemini - will lead NAX’s technology platform as it works on the development and deployment of enterprise-grade solutions to power digital asset economies. The platform’s current focus areas include coin & tokenization solutions, payment & disbursement processing, aggregated blockchain solutions and deployment services.
The arrival of Patrick Nicolet coincides with the appointment of Dr. Heiner Leisten as Chair of the Genesis Project, NAX’s development platform, and Joe Euteneuer as Chair of LiQid, NAX’s securitization platform. Both already sit on the NAX Board alongside high-profile business figures such as Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank.
Jeff Schumacher, CEO and Founder, NAX said: “Patrick is a world-class technologist and business leader and brings vast experience to the team. His arrival further strengthens the NAX ecosystem; a development platform that mines corporate assets to create asset-backed ventures and markets, a technology platform that provides technology tools and solutions to power digital assets, and a securitization platform to make corporate assets tradeable. With Heiner, Patrick, and Joe at the helm of each, alongside our broader leadership team, we’re building an infrastructure that can fully realize the trillions of dollars of dormant value residing in corporate assets.”
NAX formally launched in January 2021 after two and a half years in stealth development. It focuses on building new markets and ecosystems around corporate assets. Led by serial entrepreneur Jeff Schumacher, NAX comprises three distinct but complementary platforms that provide a new lifecycle to repurpose corporate assets:
-
Creating asset backed ventures and markets
NAX’s development platform Genesis Project mines dormant corporate assets to create asset-backed ventures and markets.
-
Leveraging assets for DeFi
NAX’s technology platform Bridge deploys enterprise-grade technology solutions to power digital asset economies.
-
Making alternative assets tradeable
NAX’s trading platform LiQid securitizes corporate assets to make them tradeable.
Schumacher added: “The vast majority of assets globally are not listed. At NAX, we’re building an infrastructure to change that. From seed to securitization, we unlock value from underutilized corporate assets and, in doing so, are building next generation markets.”
About NAX
NAX enables a corporate partner to realize the full potential of its proprietary assets through the development of new asset-backed ventures and securities.
From seed to securitization, NAX co-leads the commercialization of these initiatives alongside its partners. It has three distinct but complementary platforms to repurpose corporate assets: a development platform, a technology platform and a securitization platform.
NAX maintains its headquarters in Manhattan Beach, CA and has offices in Palo Alto, New York, London, Paris, Zurich and Frankfurt.
For more information, visit http://www.naxgrp.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005501/en/
Contact information
Media contacts
Vested
Danny Calogero
nax@fullyvested.com
+447891 563 294
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom